NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial

NCT06342037 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Tiragolumab
DRUG: Atezolizumab
DRUG: Ipilimumab

Sponsor

The Netherlands Cancer Institute

Collaborators

[object Object]